Paper Details

  1. Home
  2. Paper Details

Long-term follow-up of antiviral combination therapy in chronic hepatitis B.

Author: BerkL, ChamuleauR A, De ManR A, Den OudenJ, HeijtinkR A, ReesinkH W, SchalmS W, ten KateF J

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

A study of patients with chronic hepatitis B e-positive hepatitis found that combination therapy with interferon and desciclovir was most effective in achieving HBe seroconversion, followed by interferon alone and acyclovir. Seroconversion was associated with initial low viral replication and transient aminotransferase elevations.
Paper Details　
Original Abstract of the Article :
For patients with chronic hepatitis B e (HBe)-positive hepatitis, long-term results of pilot studies with lymphoblastoid interferon-alpha, acyclovir, or a combination, and of a randomized controlled trial of interferon/desciclovir combination therapy are presented. HBe seroconversion was observed in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3044080

データ提供：米国国立医学図書館（NLM）

Combating Chronic Hepatitis B: A Journey Through Antiviral Therapy

Imagine a desert oasis, its water source threatened by an encroaching sandstorm. Chronic hepatitis B, a viral infection that affects the liver, is a formidable foe, much like a relentless desert storm. This study explores the effectiveness of long-term antiviral combination therapy in managing chronic hepatitis B. The researchers analyzed data from pilot studies and a randomized controlled trial, examining the impact of different antiviral treatments on hepatitis B e (HBe) seroconversion and viral replication. The study also investigated the long-term effects of these therapies on liver function.

Antiviral Combination Therapy: A Potent Weapon Against Hepatitis B

The study reveals that antiviral combination therapy achieved significant HBe seroconversion in more than 40% of patients, demonstrating its effectiveness in suppressing viral replication and promoting a state of virus latency. These findings suggest that antiviral combination therapy can be a valuable tool in managing chronic hepatitis B, potentially reducing the risk of long-term complications.

Navigating the Path to Liver Health

Chronic hepatitis B is a serious condition that requires careful management. While antiviral combination therapy offers a promising approach, it is essential to consult with a healthcare professional to determine the best course of treatment. Early diagnosis and treatment are crucial for preventing the progression of liver disease and improving long-term outcomes.

Dr. Camel's Conclusion

This study highlights the effectiveness of antiviral combination therapy in managing chronic hepatitis B. The results suggest that this therapy can significantly reduce viral replication and promote a state of virus latency, offering a potential path to better liver health.

Date :
  1. Date Completed 1988-09-22
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

3044080

DOI: Digital Object Identifier

3044080

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.